Innovo Therapeutics

Innovo Therapeutics is dedicated to pioneering the next wave of protein degradation therapies, addressing critical unmet medical needs. Leveraging extensive drug discovery expertise and a unique proficiency in targeted protein degradation, Innovo Therapeutics rapidly develops an expansive compound library of novel, drug-like structures, yielding high-quality leads. The company’s powerful targeted protein degradation platform, TriNovo, is coupled with a proprietary phenotypic screening platform, enabling scientists to build and rapidly expand a high-quality, differentiated pipeline.

Innovo Therapeutics’ competitive advantage lies in its differentiated drug discovery approach, allowing for the swift advancement of its pipeline. The company continues to drive value through highly validated biology and its differentiated, high-throughput chemistry platform. With a focus on execution, Innovo Therapeutics is rapidly growing its pipeline through corporate and academic alliances. They hold worldwide exclusive rights to Rosmantuzumab, an anti-RSPO3 mAB currently in Phase 2 clinical trials, and are actively pursuing further pharma partnership discussions to advance pipeline programs.

Operating from its primary location at 10355 Science Center Dr, San Diego, California 92121, US, and with a presence in Suzhou, CN, Innovo Therapeutics maximizes its expertise, productivity, and efficiency. The Innovo US team’s proven drug discovery experience leverages internal expertise and optimizes China’s rich pre-clinical resources and infrastructure to build a world-class, global biopharmaceutical company. We invite the management team at Innovo Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further amplify their reach and success.